We have prioritised for the success of our strategy, this is how.
The low-cost production environment will enable the company to remain competitive and to achieve its high-margin strategy.
NEOPHARM’s focus on the highest-quality GMP/GACP certified products, will allow NEOPHARM to access various target markets, commencing with medical products and API’s , through precise control of cultivation variables.
This pro-active growth strategy will enable NEO PHARM to gain greater share and margins across the entire cannabis industry value chain.
Our large-scale, state-of-the-art facilities have been designed to satisfy the fast-growing international demand for cannabis in the medical markets.
Join our community
Stay up to date on the research and development of novel cannabinoid-based treatments as well as the rules, regulations, propositions, amendments and shifts in the medical cannabis industry.